Device Trial Radar · NCT03084510
REPRISE China - Clinical Evaluation in China
Last checked: Nov 20, 2026Latest source record: Nov 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Feb 28, 2020
Primary completion
Nov 30, 2020
Study completion Nov 30, 2020
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- Collaborators
- Quintiles, Inc.
- First posted
- Mar 21, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and effectiveness of the Lotus Edge™ Valve System for transcatheter aortic valve replacement (TAVR) in symptomatic Chinese patients with calcific, severe native aortic stenosis who are considered at high risk for surgical valve replacement.
Conditions
- Stenoses, Aortic Valve
Interventions
Lotus Edge™ Valve SystemDevice
• The Lotus Edge™ Valve System consisting of two main components: * a bioprosthetic bovine pericardial aortic valve, and * a delivery system Device sizes include 23 mm, 25 mm and 27 mm diameter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause mortalityTime frame: Through 30 days post index procedure
- Mean aortic valve pressure gradientTime frame: At 30 days post index procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cardiovascular Institute and Fu Wai Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.